CD8A and neoplasm: Moreover, tumor mutational load could be potential predictive biomarker forPD-1/PD- L1 blockade therapy: it is demonstrated that tumors with high mutationalload are likely more immunogenic, due to higher production of neoantigens andconsequent stimulation of neoantigen-specific CD4+ and CD8+ T cells [47].